CHM Secures Non-Dilutive and Equity Funding to Advance Lead Clinical Asset
Chimeric Therapeutics Limited (ASX: CHM) has secured firm commitments totalling AU$8.4 million to fully fund its CHM CDH17 CAR-T clinical trial through the completion of Phase 1, removing near-term funding risk for its lead asset. The capital raising comprises an AU$4.4 million two-tranche placement and an AU$4.0 million convertible note from a US institutional investor.
The placement will be issued at AU$0.003 per share, with 1-for-1 attaching options exercisable at AU$0.005, and includes a US$2.0 million (approximately AU$3.0 million) cornerstone commitment from a US-based family office. Proceeds will support progression of the next patient cohort at an increased dose level, following encouraging early safety and disease control signals, alongside advancement of CORE-NK programs. In parallel, the Company has initiated a strategic and cost review, including expense reduction, proposed share consolidation, board renewal and a streamlined clinical oversight model, positioning Chimeric for a more disciplined execution phase into 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
CHM Secures Non-Dilutive and Equity Funding to Advance Lead Clinical Asset
Chimeric Therapeutics Limited (ASX: CHM) has secured firm commitments totalling AU$8.4 million to fully fund its CHM CDH17 CAR-T clinical trial through the completion of Phase 1, removing near-term funding risk for its lead asset. The capital raising comprises an AU$4.4 million two-tranche placement and an AU$4.0 million convertible note from a US institutional investor.
The placement will be issued at AU$0.003 per share, with 1-for-1 attaching options exercisable at AU$0.005, and includes a US$2.0 million (approximately AU$3.0 million) cornerstone commitment from a US-based family office. Proceeds will support progression of the next patient cohort at an increased dose level, following encouraging early safety and disease control signals, alongside advancement of CORE-NK programs. In parallel, the Company has initiated a strategic and cost review, including expense reduction, proposed share consolidation, board renewal and a streamlined clinical oversight model, positioning Chimeric for a more disciplined execution phase into 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au